EUCTR2006-005728-17-IT进行中（未招募）不适用
Hormone-refractory Prostate cancer first Line Intermittent Taxotere and Estramustine. - ND
AZIENDA PROVINCIALE PER I SERVIZI SANITARI DELLA PROVINCIA AUTONOMA DI TRENTO0 个研究点目标入组 128 人开始时间: 2007年1月16日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 128
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •1 histologically proven diagnosis of prostate cancer 2 previous therapy with LHRH-analogue 3 PSA value rise during second line hormonal manipulation 4 performance status less than ECOG 2 5 life expectancy more than 12 weeks 6 adequate bone marrow function 7 written consent informed 8 patients ability to fill the quality of life questionnaire
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1 disease progression without PSA rise 2 active infection 3 previous chemotherapy for prostate cancer 4 non adequate liver or renal functions 5 major diseases limiting chemotherapy 6 major cardiovascular diseases
研究者
相似试验
招募中
1 期
Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (THUNDER): A Two-part Phase 2/3 TrialProstate cancerCTIS2022-501551-90-00Gasthuiszusters Antwerpen493
Unknown
不适用
Circulating Tumor Cells and Survival in Hormone Refractory Prostate Cancer (HRPC) Patients Receiving ChemotherapyHormone Refractory Prostate CancerProstate CancerNCT00133900Immunicon276
Unknown
2 期
Phase II Study of RAD001 in a Neoadjuvant Setting in Men With Intermediate or High Risk Prostate CancerProstate CancerNCT00657982Sheba Medical Center15
已完成
1 期
Radionuclide therapy using Lutetium-177 prostate specific membrane antigen (PSMA): a pilot study in men with castrate-resistant prostate cancer (LuPSMA trial)Cancer - ProstateProstate CancerACTRN12615000912583Peter MacCallum Cancer Centre30
已完成
不适用
Outcome study of hormonal therapy for prostate cancer in JapaProstate cancerJPRN-C000000252J-CaP study group24,000